A Phase 2 interventional study of ETC-1002 and Placebo in Hypercholesterolemia, sponsored by Esperion Therapeutics, Inc.. Completed at 40 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-29.
Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 10th largest by enrollment, is one of 2 that started in 2014, is one of 10 in phase 2, and was the 4th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
By country, each count listing its studies:
bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 133 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 126 across the 21 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 6 most frequent:
Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 15 studies in Hypercholesterolemia by Esperion Therapeutics, Inc., this one is the 9th largest by enrollment, is one of 2 that started in 2014, is one of 9 in phase 2, and was the 4th registered.
Esperion Therapeutics, Inc.’s Hypercholesterolemia studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Esperion Therapeutics, Inc.’s 15 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to see how ETC-1002 is tolerated in the body and how ETC-1002 affects the levels of LDL-C (bad cholesterol) in patients receiving ongoing statin therapy.
Approximately 132 hypercholesterolemic patients already taking statin therapy to treat elevated LDL-C will be randomized in a ratio of 1:1:1 to receive either ETC-1002 (120 mg or 180 mg dose), or placebo for 12 weeks in addition to ongoing statin therapy. This study will explore the safety and efficacy of ETC-1002 when given to patients receiving statin therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Orally, once daily in morning as capsules
Drug: ETC-1002 · Drug: Statin Therapy
Orally, once daily in morning as capsules
Drug: ETC-1002 · Drug: Statin Therapy
Orally, once daily in morning
Drug: Placebo · Drug: Statin Therapy
ETC-1002 capsules, taken once daily oral
Placebo capsules, taken once daily oral
Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.
Percent change from baseline in calculated low density lipoprotein-cholesterol (LDL-C)
Time frame: 12 weeks
Percent change in non-high-density lipoprotein cholesterol (non-HDL-C)
Time frame: 12 weeks
Percent change in apolipoprotein B (ApoB)
Time frame: 12 weeks
Percent change in total cholesterol (TC)
Time frame: 12 weeks
Percent change in high-sensitivity C-reactive protein (hsCRP)
Time frame: 12 weeks
Percent change in triglycerides (TG)
Time frame: 12 weeks
Percent change in lipoprotein particle number
Time frame: 12 weeks
Safety using adverse event reports; clinical laboratory results
Time frame: 12 weeks
Safety using adverse event reports; vital signs
Time frame: 12 weeks
Pharmacokinetic plasma trough concentrations of ETC-1002 and metabolite 15228
Time frame: 12 weeks
The record gives a start of Mar 2014, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid